Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?

Nature Clinical Practice Urology volume 2, pages 20–21 (2005)Cite this article

Tannock I F et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512

boxed-text

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tannock IF et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756–1764

    Article  CAS  Google Scholar 

  2. Kantoff PW et al. (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of cancer and leukemia group B 9182 study. J Clin Oncol 17: 2506–2513

    Article  CAS  Google Scholar 

  3. Petrylak DP et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–1520

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Suzanne Farley, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Chief of Medical Oncology at the San Camillo and Forlanini Hospitals, Rome, Italy

    Cora N Sternberg

Authors
  1. Cora N Sternberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cora N Sternberg.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sternberg, C. Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?. Nat Rev Urol 2, 20–21 (2005). https://doi.org/10.1038/ncpuro0066

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0066

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing